520 results about "Rash" patented technology

A method for manufacturing molecular chlorine dioxide, by the addition of potassium iodide to a solution of alkali metal chlorite. The metal chlorite and the potassium iodide are kept separate, until the need for the generation of chlorine dioxide arises-to ensure long-shelf life. After initiation or activation of the chlorite anion to form chlorine dioxide, the beneficial properties of chlorine dioxide can be used, for different health and cosmetic purposes. Such uses include the treatment of herpes, dandruff, acne, skin rashes (e.g. poison ivy), ulcers, bed sores, warts, nail fungus, athletes foot, sun burn and gum disease; and as an antiseptic, disinfectant, and general deodorant form refrigerator sprays to oral mouthrinses.

A cushioned wristband includes a carrier having a multi-layered band portion and a strap sewn to the back of the band portion of the carrier. The band has a surface with loop material and the strap has a surface of hook material, the hook and loop surfaces being intended to secure the band in place as it is wrapped about a patient's appendage. The strap is appropriately sized to insert through one or both of two cinch slots of a self-laminating hang tag which may be printed with patient information and separated from a sheetlet or page sized business form processed through a printer for imaging of patient information thereon. The band portion of the carrier includes a cushioned layer of soft foamy or spongy material for contacting a patient's skin to thereby substantially eliminate any possibility for abrasion, rash, or other irritation or injury to the patient through wearing of the wristband.

A baby wipe/rash cream dispenser that allows the user to retrieve baby wipes and rash medication with one hand while using the other hand to maintain the safety of the baby. The baby wipe/rash cream dispenser comes in a first embodiment having a moisture tight seal and two compartments one for baby wipes and one for rash cream which are each accessible when the lid is open. The second embodiment includes a housing having a sealable lid compartment for baby wipes and a separate lid compartment for rash cream that is provided with a pump mechanism for allowing the user to pump the rash cream from the reservoir without the need for opening the lid.

Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by C_max below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml. The composition provides pulsatile release of milnacipran to produce a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.

We present, in exemplary embodiments of the present invention, novel systems and methods for syndromic surveillance that can automatically monitor symptoms that may be associated with the early presentation of a syndrome (e.g., fever, coughing, sneezing, runny nose, sniffling, rashes). Although not so limited, the novel surveillance systems described herein can be placed in common areas occupied by a crowd of people, in accordance with local and national laws applicable to such surveillance. Common areas may include public areas (e.g., an airport, train station, sports arena) and private areas (e.g., a doctor's waiting room). The monitored symptoms may be transmitted to a responder (e.g., a person, an information system) outside of the surveillance system, such that the responder can take appropriate action to identifying, treat and quarantine potentially infected individuals, as necessary.

The patch agent of the present invention is a patch agent comprising a support made of a synthetic fiber and an adhesive layer mounted on the support, and having a bending resistance of 10 to 30 mm and a probe tack value of 0.25 to 1.2 N. The patch agent of the present invention can fully be prevented from peeling off at the time of application and can fully suppress the rash of skin and the pain upon peeling.

This invention relates to methods and compositions for preventing and treating skin rash, such as perineal dermatitis, associated with enzymatic dermatitis. More particularly, this invention relates to compounds containing procyanidins, which possess trypsin and/or chymotrypsin inhibitory activity and are suitable for use in compositions for preventing and treating skin irritation caused by protease exposure, such as perineal dermatitis.

A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by T_max at 4-10 hours and an approximately linear drop-off thereafter and C_max below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml. The composition provides a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.

The invention describes a method of producing extracts from the seeds of meadowfoam, brassicas and crambe plants. A number of subsidiary processes and steps are shown in order to extract differing fractions of oil. Products produced from the above method are also described including uses and methods of these products which include a variety of skin conditions including eczema, facial eczema, dermatitis, external ulcers, welts, rashes, insect bites, allergic reactions and other irritations, burns, wounds, psoriasis, acneiform eruptions, dryness, dry skin, irritation, skin atrophy, secondary infections and the like. The extracts are also described as being a useful compound for treatment of the symptoms of such skin conditions as described above. In particular the use and extraction of glucosinolate (GSL), thiocyanates (TCL) and isothiocyanates (ITCL) is described.

Compositions that express a pressure of carbon dioxide are beneficial when used for the care of wounds, and when externally applied to skin damaged by cuts, burns, abrasions, excessive radiation, or from rashes and similar dysfunctions.

The present invention provides low cost and highly effective method for the removal of arsenic and Cr(III&VI) from contaminated water using zinc peroxide nanoparticles (20±5 nm) capped with glycerol/PVP/TEA upto the permissible range of drinking water. As Arsenic and chromium occurs naturally in the earth's crust. When rocks, minerals, and soil erode, they release arsenic and chromium into groundwater. Arsenic and chromium occurs naturally in varying amounts in groundwater in various parts of country from ppb level to ppm level. The average concentration of arsenic and chromium as per USEPA standard in drinking water it is 10 parts per billion and 0.05 ppm (50 ppb) respectively. In drinking water the level of chromium is usually low as well, but contaminated water may contain the dangerous Cr(III&VI). Although Cr(III) is an essential nutrient for humans and shortages may cause heart problems, disruptions of metabolisms and diabetes. But the uptake of too much Cr(III) can cause health effects as well, for instance skin rashes. Cr(VI) is known to cause various health effects Skin rashes, upset stomachs, respiratory problems, weakened immune systems, kidney and liver damage and lung cancer The persons who are drinking water having upto 50 ppb of arsenic and 0.05 ppm chromium over for many years could experience skin damage or problems with their circulatory system, and may have an increased risk of getting cancer. Keeping the above facts we developed a cost effective nanoparticles for the removal of Arsenic and Cr(III&VI) from potable water upto potable range.

The present invention discloses certain di- and polyvalent metal zeolite compounds (formula I) for topical delivery of biological and skin and hair care agents. The method of treating skin and hair condition via topical application of said zeolite compounds is also disclosed. The said method provides a treatment for topical condition, which includes alleviation of skin conditions such as skin rash including diaper rash, dry skin, scalp dandruff, broken or chafed skin, sunburn, skin damage from UV, skin irritation, acne including excess facial oil and facial pore size; darkened skin including age spots, dark circles around the eyes, and discoloration of skin from stretch marks; skin aging including wrinkles and fine lines; loss of collagen including thinning skin and loss of skin pliability; body odor, including oral cavity odor, arm-pit odor, and incontinence odor; cellular inflammation including intracellular and extra cellular inflammation; premature hair aging including premature hair loss hair graying; malfunction of tyrosinase group of enzymes, malfunction of matrix metalloprotease group of enzymes; and combinations thereof. The said method also provides topical delivery of certain metals, including trace metals, and certain zirconium aluminum amino acids that provide antiperspirant benefits;

Copper ion treatments for dermatological areas of the body include solutions, creams, lotions, gels, foams, wound dressings, skin patches and suture material, each containing copper ions that bring about therapeutic effects when the copper ion treatments are applied to dermatological tissue. Methods of treating dermatological areas of the body include treatments for use on the skin and nails to treat conditions including disease, infection, inflammation, damaged or injured tissue, tissue needing to be sutured, rashes and other undesirable dermatological conditions.

The present invention relates to a pure traditional Chinese medicine mask with effects of spot removing, acne removing and whitening, wherein the mask comprises mung bean, ma-yuen jobstears seed, seaweed, lemon, aloe, cordyceps sinensis, pangolin piece, pearl, dangshen, peppermint, safflower, peach seed, almond, angelica archang lica, largehead atractylodes rhizome, common bletilla tuber, baikal skullcap root, dan-shen root, silkworm larva, common motherwort herb, fragrant solomonseal rhizome, smilax china, ginkgo leaf, fortune firethorn fruit and root, and other main raw materials, and is a full-nature nutritional substance with no toxic-side effect. With the mask, a conditioning effect is provided based on skin detoxification cycle, skin metabolism cycle is promoted, pores are cleaned and minimized, problems of dull complexion, large pores, dark yellow complexion, oiliness, acne, comedo, yellow qi and the like of the whole skin can be conditioned and cleaned, significant treatment effects are provided for acne, rash, comedo and the like, and functions of nutrition, skin health care and whitening are provided. In addition, the traditional Chinese medicine mask is used in more than 200 beautifying institutions in the region, and is compensatedly used in more than 600 national beautifying institutions according to contract agreements, wherein more than 80 beautifying chain institutions are included.

The present invention discloses a method of treating skin conditions that include acne, skin wrinkles, age spots, pimples, scars, skin rash including diaper rash, dry skin, scalp dandruff, scalp dry skin, darkened skin, skin discoloration, broken skin, chafed skin, sunburn, skin damage from UV, skin irritation, body odor, or a combination thereof, via topical application of certain clathrates of zinc zeolite with non-antibiotic organic agents.

The invention relates to the technical field of medical plastic surgery, in particular to the technical field of facial filling and anti-wrinkle, in particular, it is an injection filling cosmetic modification anti-aging, skin beautification and facial rejuvenation material. The preparation formula of the present invention includes hyaluronic acid, collagen, vitamin E and PLGA. The preparation method comprises: 1) preparing high-viscosity gel; 2) preparing PLGA nano-microspheres; 3) fully mixing high-viscosity gel and PLGA nano-microspheres; 4) sterilizing and filling. Compared with the prior art, the present invention has the beneficial effect that: the combined use of collagen and hyaluronic acid reduces skin erythema, swelling, hardening or itching, muscle pain, urticaria or Other symptoms such as rash. It reduces the probability of severe complications such as peripheral blood circulation embolism, skin necrosis, retinal artery embolism, and cardiocerebral artery embolism that may be caused by simple hyaluronic acid injection, and the safety of product use is improved.

The embodiment of the invention discloses infant diaper rash cream. The infant diaper rash cream comprises a skin conditioning agent, emollient, humectant, absorbent, emulsifier, antioxidant, a thickening agent and deionized water; the skin conditioning agent comprises allantoin, bisabolol, borneol, and witchhazel extract; the emollient comprises ethylhexyl palmitate, polydimethylsiloxane, cyclopentasiloxane, cyclohexasiloxane, synthetic beeswax, camellia-seed oil, and deep-sea crambe abyssinica seed oil. Various ingredients of the diaper rash cream are reasonably compounded, besides the moisturizing effect of the existing diaper rash cream, multiple pure natural plant extracts are adopted so as to form a layer of protective film on the surface of the skin, the skin friction is reduced, the excrement can be isolated, thereby effectively preventing the infant buttock; the product further has bacteriostatic and anti-inflammatory effects, the skin can be further relieved, so as to furtherachieve the purposes of improving the treating the read buttock. The diaper rash cream disclosed by the invention is stable in performance, safe and non-irritant, and is an expected and healthy infant skin protection product.